Arterial Thrombosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Arterial thrombosis pipeline market report provides a comprehensive overview on the therapeutics under development for Arterial thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Arterial thrombosis and features dormant and discontinued projects.
Key Targets in the Arterial Thrombosis Pipeline Drugs Market
In the Arterial Thrombosis pipeline drugs market the key targets are Coagulation Factor XI, Plasminogen Activator Inhibitor 1, 12-S-Hydroxy-5,8,10,14-Eicosatetraenoic Acid Receptor, Collagen, Integrin Alpha 2, Integrin Beta 1, Myosin 9, P2Y Purinoceptor 1, P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y, and Prostaglandin G/H Synthase 1.
Arterial Thrombosis Drugs Market, by Targets
For more target insights, download a free report sample
Key MoA in the Arterial Thrombosis Pipeline Drugs Market
Coagulation Factor XI Inhibitor has the highest number of pipeline products followed by Plasminogen Activator Inhibitor 1 Inhibitor, 12-S-Hydroxy-5,8,10,14-Eicosatetraenoic Acid Receptor Antagonist, Collagen Inhibitor, Integrin Alpha 2 Antagonist, Integrin Beta 1 Antagonist, Myosin 9 Inhibitor, P2Y Purinoceptor 1 Antagonist, P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y, and Prostaglandin G/H Synthase 1 Antagonist.
Arterial Thrombosis Pipeline Drugs Market, by MoA
To get more insights on key MoA, download a free sample report
Arterial Thrombosis Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Arterial Thrombosis pipeline drugs market are Oral, Subcutaneous, Intravenous, and Parenteral. Oral has the maximum number of pipeline products.
Arterial Thrombosis Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Arterial Thrombosis Pipeline Drugs Market
The key molecule types in the Arterial Thrombosis pipeline drugs market are Small Molecule, Antisense RNAi Oligonucleotide, Biologic, Monoclonal Antibody, Peptide, Recombinant Peptide, and Synthetic Peptide.
Arterial Thrombosis Pipeline Drugs Market, by Molecule Type
To get more insights on key molecule types, download a free sample report
Major Companies in the Arterial Thrombosis Pipeline Drugs Market
The major companies in the Arterial Thrombosis pipeline drugs market are Jiangsu Hengrui Medicine Co Ltd, Oasis Pharmaceuticals LLC, Anthos Therapeutics Inc, Astellas Pharma Inc, GLSynthesis Inc, MDI Therapeutics Inc, Protheragen Inc, and Suzhou Ribo Life Sciences Co Ltd.
Arterial Thrombosis Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Arterial Thrombosis Pipeline Drugs Market Overview
Key Targets | Coagulation Factor XI, Plasminogen Activator Inhibitor 1, 12-S-Hydroxy-5,8,10,14-Eicosatetraenoic Acid Receptor, Collagen, Integrin Alpha 2, Integrin Beta 1, Myosin 9, P2Y Purinoceptor 1, P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y, and Prostaglandin G/H Synthase 1 |
Key Mechanisms of action | Coagulation Factor XI Inhibitor, Plasminogen Activator Inhibitor 1 Inhibitor, 12-S-Hydroxy-5,8,10,14-Eicosatetraenoic Acid Receptor Antagonist, Collagen Inhibitor, Integrin Alpha 2 Antagonist, Integrin Beta 1 Antagonist, Myosin 9 Inhibitor, P2Y Purinoceptor 1 Antagonist, P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y, and Prostaglandin G/H Synthase 1 Antagonist |
Key Routes of Administration | Oral, Subcutaneous, Intravenous, and Parenteral |
Key Molecule Types | Small Molecule, Antisense RNAi Oligonucleotide, Biologic, Monoclonal Antibody, Peptide, Recombinant Peptide, and Synthetic Peptide |
Major Companies | Jiangsu Hengrui Medicine Co Ltd, Oasis Pharmaceuticals LLC, Anthos Therapeutics Inc, Astellas Pharma Inc, GLSynthesis Inc, MDI Therapeutics Inc, Protheragen Inc, and Suzhou Ribo Life Sciences Co Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Arterial Thrombosis
- The pipeline guide reviews pipeline therapeutics for Arterial Thrombosis by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Arterial Thrombosis therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Arterial Thrombosis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Arterial Thrombosis
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective countercstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Arterial Thrombosis
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Arterial Thrombosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Astellas Pharma Inc
GLSynthesis Inc
Jiangsu Hengrui Medicine Co Ltd
MDI Therapeutics Inc
Oasis Pharmaceuticals LLC
Protheragen Inc
Suzhou Ribo Life Sciences Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Arterial Thrombosis pipeline drugs market?
In the Arterial Thrombosis pipeline drugs market the key targets are Coagulation Factor XI, Plasminogen Activator Inhibitor 1, 12-S-Hydroxy-5,8,10,14-Eicosatetraenoic Acid Receptor, Collagen, Integrin Alpha 2, Integrin Beta 1, Myosin 9, P2Y Purinoceptor 1, P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y, and Prostaglandin G/H Synthase 1.
-
What are the key mechanisms of action in the Arterial Thrombosis pipeline drugs market?
In the Arterial Thrombosis pipeline drugs market the key mechanisms of action are Coagulation Factor XI Inhibitor, Plasminogen Activator Inhibitor 1 Inhibitor, 12-S-Hydroxy-5,8,10,14-Eicosatetraenoic Acid Receptor Antagonist, Collagen Inhibitor, Integrin Alpha 2 Antagonist, Integrin Beta 1 Antagonist, Myosin 9 Inhibitor, P2Y Purinoceptor 1 Antagonist, P2Y Purinoceptor 12 (ADP Glucose Receptor or P2Y12 Platelet ADP Receptor or SP1999 or P2T(AC) or P2Y(AC) or P2Y, and Prostaglandin G/H Synthase 1 Antagonist.
-
What are the key routes of administration in the Arterial Thrombosis pipeline drugs market?
The key routes of administration in the Arterial Thrombosis pipeline drugs market Oral, Subcutaneous, Intravenous, and Parenteral.
-
What are the key molecule types in the Arterial Thrombosis pipeline drugs market?
The key molecule types in the Arterial Thrombosis pipeline drugs market are Small Molecule, Antisense RNAi Oligonucleotide, Biologic, Monoclonal Antibody, Peptide, Recombinant Peptide, and Synthetic Peptide.
-
What are the major companies in the Arterial Thrombosis pipeline drugs market?
In the Arterial Thrombosis pipeline drugs market the major companies are Jiangsu Hengrui Medicine Co Ltd, Oasis Pharmaceuticals LLC, Anthos Therapeutics Inc, Astellas Pharma Inc, GLSynthesis Inc, MDI Therapeutics Inc, Protheragen Inc, and Suzhou Ribo Life Sciences Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.